Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP
Completed
- Conditions
- Ametropia
- Registration Number
- NCT04654455
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an innovative eye drops stimulating corneal innervation. To date no study has quantified the improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Age over 18
- Planned bilateral LASIK surgery
- Use of Repadrop as postoperative eye drops
- Patient agreement to participate
Read More
Exclusion Criteria
- History of corneal pathology
- Diabetes
- History of treatment with REPADROP® or CACICOL® or NGF® (other eye drops which are no longer available on the market to date but which would also improve corneal healing)
- Ongoing treatment with topical cyclosporine
- Presence of punctal plugs
- Adults who are the subject of a legal protection measure (guardianship, curators)
- Pregnant or breastfeeding women
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Variation in OSDI (Ocular Surface Disease Index) score 3 Months Variation in OSDI (Ocular Surface Disease Index) score between 1 month and 3 months post-LASIK. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hôpital Edouard Herriot
🇫🇷Lyon, Rhone, France